Drug
Sel 212
Sel 212: highest development phase Phase 2, developed by Selecta Biosciences. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Selecta Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| SEL-212 NCT03905512 | Phase 2 | Chronic Gout |
| SEL-212 NCT02959918 | Phase 2 | Gout Chronic |
Latest
No recent events.
Follow Sel 212 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.